|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biogen thinks it has another Alzheimer's contender, and although BIIB080 missed the mark in Phase 2, it's full steam ahead with pivotal studies — kind of. “We don’t want to be too impulsive about moving to Phase 3,” Biogen's Priya Singhal told Max Gelman. Read more from Max here. |
|
|
|
Alex Hoffman |
Senior Copy Editor, Endpoints News
|
|
|
|
|
|
|
by Max Gelman
|
Here we go again? Biogen reported heavily anticipated Alzheimer’s data, saying its tau-targeting drug BIIB080 missed its primary endpoint in a Phase 2 study but... | |
|
|
|
|
|
|
|
|
by Elizabeth Cairns
|
A combination of AstraZeneca's Imfinzi with Pfizer and Astellas’ Padcev kept more bladder cancer patients alive than standard of care, the company said Thursday. AstraZeneca... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
💸 A Series A extension: US-China biotech Degron Therapeutics has collected an additional $40 millionfor its molecular glue degrader platform. The San Diego
and... | |
|
|
|
|
|
|
by Ayisha Sharma
|
BeOne Medicines has clinched US accelerated approval for its drug sonrotoclax in mantle cell lymphoma (MCL), marking the start of its bid to challenge AbbVie... | |
|
|
|
 |
|
Regenxbio CEO Curran Simpson at Endpoints' #JPM26 event (Brian Benton Photography) |
|
|
|
by Lei Lei Wu
|
Regenxbio said Thursday that its Duchenne muscular dystrophy gene therapy met the bar in a pivotal study, and it’s aiming for FDA approval in 2027... | |
|
|
|
|
|
